In the realm of road safety and the evolution toward automated driving, Advanced Driver Assistance and Automated Driving (ADAS/AD) systems play a pivotal role. As the complexity of these systems grows, comprehensive testing becomes imperative, with virtual test environments becoming crucial, especially for handling diverse and challenging scenarios. Radar sensors are integral to ADAS/AD units and are known for their robust performance even in adverse conditions. However, accurately modeling the radar's perception, particularly the radar cross-section (RCS), proves challenging. This paper adopts a data-driven approach, using Gaussian mixture models (GMMs) to model the radar's perception for various vehicles and aspect angles. A Bayesian variational approach automatically infers model complexity. The model is expanded into a comprehensive radar sensor model based on object lists, incorporating occlusion effects and RCS-based detectability decisions. The model's effectiveness is demonstrated through accurate reproduction of the RCS behavior and scatter point distribution. The full capabilities of the sensor model are demonstrated in different scenarios. The flexible and modular framework has proven apt for modeling specific aspects and allows for an easy model extension. Simultaneously, alongside model extension, more extensive validation is proposed to refine accuracy and broaden the model's applicability.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11014321 | PMC |
http://dx.doi.org/10.3390/s24072177 | DOI Listing |
Clinics (Sao Paulo)
January 2025
Department of Respiratory Medicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
Background: Post-acute COVID-19 Syndrome (PACS) occurs in some COVID-19 patients long after acute infection and significantly affects patients' health. However, the mechanism by which PACS develops is unknown. Myosin light chain 9 (Myl9), produced by activated platelets, plays a role in immune dysregulation and microthrombi formation during acute COVID-19.
View Article and Find Full Text PDFFront Cell Infect Microbiol
January 2025
Department of Clinical Laboratory Medicine Center, Inner Mongolia Autonomous Region People's Hospital, Hohhot, Inner Mongolia, China.
Introduction: This study aims to utilize proteomics, bioinformatics, and machine learning algorithms to identify diagnostic biomarkers in the serum of patients with acute and chronic brucellosis.
Methods: Proteomic analysis was conducted on serum samples from patients with acute and chronic brucellosis, as well as from healthy controls. Differential expression analysis was performed to identify proteins with altered expression, while Weighted Gene Co-expression Network Analysis (WGCNA) was applied to detect co-expression modules associated with clinical features of brucellosis.
Genome Med
January 2025
Department of Epidemiology of Microbial Disease, Yale School of Public Health, 60 College Street, New Haven, CT, USA.
Background: Mixed infection with multiple strains of the same pathogen in a single host can present clinical and analytical challenges. Whole genome sequence (WGS) data can identify signals of multiple strains in samples, though the precision of previous methods can be improved. Here, we present MixInfect2, a new tool to accurately detect mixed samples from Mycobacterium tuberculosis short-read WGS data.
View Article and Find Full Text PDFSci Rep
January 2025
BioResource Research Center, RIKEN, 3-1-1, Koyadai, Tsukuba, 305-0074, Ibaraki, Japan.
Omics data provide a plethora of quantifiable information that can potentially be used to identify biomarkers targeting the physiological processes and ecological phenomena of organisms. However, omics data have not been fully utilized because current prediction methods in biomarker construction are susceptible to data multidimensionality and noise. We developed OmicSense, a quantitative prediction method that uses a mixture of Gaussian distributions as the probability distribution, yielding the most likely objective variable predicted for each biomarker.
View Article and Find Full Text PDFTau exhibits change in both spatial extent and density of pathology along the Alzheimer's disease (AD) spectrum with each aspect contributing to the overall burden of pathological tau. Nevertheless, studies using Tau PET have measured either magnitude using standardized uptake value ratios (SUVRs) or extent using number of Tau+ regions. We hypothesized that combining these two dimensions into a single measure of Magnitude and eXtent, Tau-MaX, would provide improved quantification of global tau burden as well as allowing for a region-agnostic measure of global tau burden that does not require a pre-specified region of interest (ROI) or meta-ROI.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!